Oral Disease-modifying Antirheumatic Drugs and Immunosuppressants with Antiviral Potential, Including SARS-CoV-2 Infection: a Review

Overview

Journal Ther Adv Musculoskelet Dis

Date 2020 Sep 21

PMID 32952617

Citations 5

Authors

Y C Tsai

T F Tsai

Affiliations

Soon will be listed here.

Abstract

Lay Summary: Immunosuppressants often raise the concern of infection risks, especially for patients with underlying immune disorders. However, some disease-modifying antirheumatic drugs (DMARDs) with inherent antiviral activity would be a reasonable choice in the situation of concomitant viral infections and flare up of autoimmune diseases. This review covers DMARDs of treatment potential for SARS-CoV-2 in part I, and antiviral mechanisms plus trial evidence for viruses other than SARS-CoV-2 in part II.

Citing Articles

Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.

Taylor P, Choy E, Baraliakos X, Szekanecz Z, Xavier R, Isaacs J Rheumatology (Oxford). 2023; 63(2):298-308.

PMID: 37624925 PMC: 10836981. DOI: 10.1093/rheumatology/kead448.

In Silico Study towards Repositioning of FDA-Approved Drug Candidates for Anticoronaviral Therapy: Molecular Docking, Molecular Dynamics and Binding Free Energy Calculations.

Qayed W, Ferreira R, Silva J Molecules. 2022; 27(18).

PMID: 36144718 PMC: 9505381. DOI: 10.3390/molecules27185988.

COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients.

Szekanecz Z, Balog A, Constantin T, Czirjak L, Geher P, Kovacs L Expert Rev Mol Med. 2022; 24:e13.

PMID: 35311631 PMC: 8943223. DOI: 10.1017/erm.2022.10.

Quantitative analysis of optical coherence tomography imaging in patients with different severities of hydroxychloroquine toxicity.

Membreno R, de Silva T, Agron E, Keenan T, Cukras C Br J Ophthalmol. 2022; 107(6):849-855.

PMID: 35288440 PMC: 11323113. DOI: 10.1136/bjophthalmol-2021-319197.

Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19.

Maslennikov R, Ivashkin V, Vasilieva E, Chipurik M, Semikova P, Semenets V Pulm Pharmacol Ther. 2021; 69:102039.

PMID: 34023513 PMC: 8137353. DOI: 10.1016/j.pupt.2021.102039.

References

Watanabe N, Yasuda H, Aota Y, Ando J, Aoyama T, Tanaka M . Reactivation of hepatitis B virus during treatment with hydroxyurea in an elderly patient with essential thrombocythemia. Geriatr Gerontol Int. 2015; 15(6):812-3. DOI: 10.1111/ggi.12461. View

Boelaert J, Sperber K, Piette J . The additive in vitro anti-HIV-1 effect of chloroquine, when combined with zidovudine and hydroxyurea. Biochem Pharmacol. 2001; 61(12):1531-5. DOI: 10.1016/s0006-2952(01)00576-7. View

Montealegre Sanchez G, Reinhardt A, Ramsey S, Wittkowski H, Hashkes P, Berkun Y . JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018; 128(7):3041-3052. PMC: 6026004. DOI: 10.1172/JCI98814. View

Smith K, Germain M . Leflunomide: an immune modulating drug that may have a role in controlling secondary infections with review of its mechanisms of action. J Drugs Dermatol. 2015; 14(3):230-6. View

Rutschmann O, Opravil M, Iten A, Malinverni R, Vernazza P, Bucher H . A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS. 1998; 12(8):F71-7. DOI: 10.1097/00002030-199808000-00003. View

Ashfaq U, Javed T, Rehman S, Nawaz Z, Riazuddin S . Lysosomotropic agents as HCV entry inhibitors. Virol J. 2011; 8:163. PMC: 3090357. DOI: 10.1186/1743-422X-8-163. View

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W . Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020; 369:m1849. PMC: 7221473. DOI: 10.1136/bmj.m1849. View

Farias K, Machado P, da Fonseca B . Chloroquine inhibits dengue virus type 2 replication in Vero cells but not in C6/36 cells. ScientificWorldJournal. 2013; 2013:282734. PMC: 3572654. DOI: 10.1155/2013/282734. View

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y . Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5):766-788. PMC: 7102550. DOI: 10.1016/j.apsb.2020.02.008. View

10.

Brighton S . Chloroquine phosphate treatment of chronic Chikungunya arthritis. An open pilot study. S Afr Med J. 1984; 66(6):217-8. View

11.

Chong A, Zeng H, Knight D, Shen J, Meister G, Williams J . Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant. 2006; 6(1):69-75. DOI: 10.1111/j.1600-6143.2005.01152.x. View

12.

Richardson P, Corbellino M, Stebbing J . Baricitinib for COVID-19: a suitable treatment? - Authors' reply. Lancet Infect Dis. 2020; 20(9):1013-1014. PMC: 7271155. DOI: 10.1016/S1473-3099(20)30270-X. View

13.

Nozaki A, Morimoto M, Kondo M, Oshima T, Numata K, Fujisawa S . Hydroxyurea as an inhibitor of hepatitis C virus RNA replication. Arch Virol. 2010; 155(4):601-5. DOI: 10.1007/s00705-010-0624-1. View

14.

Wang L, Lin Y, Huang N, Yu C, Tsai W, Chen J . Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interferon Cytokine Res. 2014; 35(3):143-56. PMC: 4350140. DOI: 10.1089/jir.2014.0038. View

15.

Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L . [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020; 49(2):215-219. PMC: 8800713. DOI: 10.3785/j.issn.1008-9292.2020.03.03. View

16.

Roger M, Anstead G . Leflunomide in the Treatment of a Pseudotumoral Genital Herpes Simplex Virus Infection in an HIV Patient. Case Rep Infect Dis. 2017; 2017:1589356. PMC: 5360951. DOI: 10.1155/2017/1589356. View

17.

Levy R, Jais J, Tourani J, Even P, Andrieu J . Long-term follow-up of HIV positive asymptomatic patients having received cyclosporin A. Adv Exp Med Biol. 1995; 374:229-34. DOI: 10.1007/978-1-4615-1995-9_20. View

18.

Savarino A, Gennero L, Chen H, Serrano D, Malavasi F, Boelaert J . Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS. 2001; 15(17):2221-9. DOI: 10.1097/00002030-200111230-00002. View

19.

Schlapfer E, Fischer M, Ott P, Speck R . Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea. AIDS. 2003; 17(11):1613-20. DOI: 10.1097/01.aids.0000072664.21517.ad. View

20.

Neely M, Kalyesubula I, Bagenda D, Myers C, Olness K . Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission. Afr Health Sci. 2003; 3(2):61-7. PMC: 2141601. View